Why has the EU been so slow to roll out a Covid vaccination programme?

Europe was not prepared for the pandemic, but it must now learn lessons and use all its financial and political resources.

By: Date: January 28, 2021 Topic: European Macroeconomics & Governance

This opinion piece was originally published on El País, Süddeutsche Zeitung and the Guardian.

El País logo

For the European Union, the rapid rollout of Covid-19 vaccines is critical to save lives and prevent health services from being stretched beyond their limits, not to mention minimising the massive economic damage from lockdowns. Unfortunately, however, though vaccinations are under way, a rapid near-term increase in infections is likely as the British variant of the virus spreads across the continent.

The problem for the EU is compounded because its vaccination programme already trails Israel, the UK and the US. The best performing EU country, Denmark, has vaccinated a meagre 3.6 people per 100, compared with 45 in Israel and more than 10 in the UK. Germany and France are even further behind. More worryingly, there are no signs that the vaccination rate in the EU is accelerating, unlike in the UK and US, where daily vaccination rates have increased substantially in the past few weeks.

The European commission and European leaders have recognised the need for rapid action. The commission intends to have 80% of those over 80 and the same percentage of health workers in the EU vaccinated by March, with 70% of the adult population vaccinated by the summer. Acceleration of the vaccination campaign is now the EU’s number one priority.

Why is the EU lagging behind? The central issue is not so much the organisational issues, but the lack of vaccines. Even Denmark has had to slow down its campaign significantly because of short supply. Many countries now report fully operational vaccine centres but insufficient vaccines. As always in such complex issues, there is no single answer as to why this is happening.

Part of the explanation is that the EU ordered too few vaccines too late. It was slow to order the BioNTech-Pfizer vaccine, even when it became the frontrunner and its efficacy had been documented. Member states hesitated to ask the EU to order more because of the novelty of the technological approach, and the commission leadership did not push hard enough for additional purchases.

Purchases were slowed down further as the EU insisted that liability in case of negative side-effects on health remains with pharma companies and therefore rejected early emergency authorisation. Many EU countries neither wanted nor asked for faster authorisation because of this liability issue. Pros and cons can be debated, but risk aversion in many EU countries is a fact. Anti-vaccination movements may have also added pressure on political decision-makers.

EU funding has also proven insufficient. Last year’s EU vaccine strategy allocated €2.7bn for advance purchase agreements, research and capacity. This was increased by €1.09bn in September. But these numbers are small compared with the $18bn the US provided through its “Operation Warp Speed”. Low EU purchase prices per vaccine might have further slowed down deliveries.

In recent days, there has been a debate about whether some pharma companies have breached the terms of the contracts with the EU. The EU has pre-financed the development and the production of the AstraZeneca vaccine and wants to now know exactly which doses have been produced and where, so it can assess whether contractual obligations are breached. An export transparency mechanism is being used as a threat to ensure that contractual obligations are fulfilled in case of breach of the contract. But AstraZeneca’s CEO has pointed out that the UK signed its contract three months before the EU and the UK factory also started operating earlier, increasing supply capacity. Moreover, according to AstraZeneca, its contract with the EU does not oblige early deliveries. Only publication of the contract can allow outsiders to judge this spat.

There is an argument that the EU was slow to develop an industrial strategy to increase production. The factories of competitors should have been mobilised as soon as possible to increase the total supply of vaccines. Sanofi has now agreed to use its factory in Frankfurt to produce additional BioNTech-Pfizer vaccines. The former Novartis factory in Marburg, Germany, will soon produce vaccines in large amounts. Why did governments not push earlier for more such agreements and increase financial resources to make them profitable for companies?

Last, the EU was not prepared for the pandemic. Only once it was under way did EU countries authorise the commission to start joint purchases. The US had institutions such as the Biomedical Advanced Research and Development Authority supporting research as early as February 2020. Building a racing machine only when the race has started means delays.

It is impossible to say how things would have gone if there had not been joint EU action. It seems safe to say that many EU countries would not have been able to negotiate faster vaccine deliveries with pharma companies. It also seems fair to say that the pressure from the Trump administration on pharma companies to deliver for the US market first was huge and EU countries individually would have had less leverage. Moreover, the politics of vaccine nationalism within the EU would have been toxic.

But the EU must now learn lessons. It needs institutions comparable with those of the US to deal with such situations. The commission’s initiative to boost the European Health Emergency Response Authority is to be supported. EU citizens should decide how much risk they are willing to take when it comes to vaccine authorisation and liability, and leaders should provide more financing for vaccine development and procurement. For now, the EU’s priority must be to mobilise all financial and political resources to increase vaccine supplies.

Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint.

Due to copyright agreements we ask that you kindly email request to republish opinions that have appeared in print to [email protected].

Read article Download PDF More on this topic

Working Paper

COVID-19 credit-support programmes in Europe’s five largest economies

This paper assesses COVID-19 credit-support programmes in five of the largest European economies, and examines how countries have dealt with trade-offs raised by the programmes.

By: Julia Anderson, Francesco Papadia and Nicolas Véron Topic: European Macroeconomics & Governance Date: February 24, 2021
Read article More on this topic More by this author


Asset bubbles won’t help our post-pandemic recovery

An unintended consequence of the virus has been ‘one of the wildest bull markets in recent economic history’ but a worsening of income distribution will have a negative impact further down the line.

By: Alicia García-Herrero Topic: Finance & Financial Regulation Date: February 23, 2021
Read article More on this topic More by this author


La dette : une obsession prématurée

Ce qui est malsain, avec la proposition d’annuler la dette, c’est le déni de réalité consistant à affirmer que l’Etat peut effacer une partie de ses engagements sans que cela ne coûte à personne.

By: Jean Pisani-Ferry Topic: European Macroeconomics & Governance Date: February 22, 2021
Read about event More on this topic

Upcoming Event


Think green act local: the role of the G20 in sustainable infrastructure

In this workshop, invited guests will discuss priorities and proposals for the Italian G20 Presidency for a green local infrastructure agenda.

Speakers: Amar Bhattacharya, Maria Demertzis, Niclas Poitiers and Gelsomina Vigliotti Topic: Energy & Climate Location: Bruegel, Rue de la Charité 33, 1210 Brussels
Read about event More on this topic

Past Event

Past Event

Money laundering and hybrid threats: Has COVID-19 made it all worse?

Will the European Union and its member states be ready to control this risk – even if competition for financial inflows intensifies?

Speakers: Arnis Praudins, Arnis Šnore, Nicolas Véron and llze Znotiņa Topic: Finance & Financial Regulation Date: February 18, 2021
Read article More on this topic More by this author



So long, credit support?

How effective have COVID-19 credit support programmes been?

By: The Sound of Economics Date: February 17, 2021
Read article More on this topic


Aiming for zero COVID-19: Europe needs to take action

Aiming for 'green zones' offers a clear path to navigate an exit from the pandemic with as little damage as possible. Europe should not miss the opportunity to build on its strength and unity.

By: Miquel Oliu Barton, Bary Pradelski and Guntram B. Wolff Topic: Global Economics & Governance Date: February 17, 2021
Read about event More on this topic

Past Event

Past Event

The role of transition finance: a conversation with EBRD President Odile Renaud-Basso

Join us in conversation with EBRD President Odile Renaud-Basso.

Speakers: Odile Renaud-Basso and Guntram B. Wolff Topic: European Macroeconomics & Governance Date: February 16, 2021
Read article More on this topic More by this author



From support to recovery: national fiscal policy in the wake of COVID-19

The EU has set ambitious goals for economic recovery: how these recovery funds are spent by member states will be critical to its success. A look into the European framework and the case of Italy.

By: The Sound of Economics Date: February 10, 2021
Read article More by this author


Will COVID accelerate productivity growth?

The COVID-19 pandemic has prompted an increasing number of rich-country firms to reduce their reliance on global supply chains and invest more in robots at home. But it is probably too soon to tell whether this switch will increase productivity growth in advanced economies.

By: Dalia Marin Topic: European Macroeconomics & Governance, Global Economics & Governance Date: February 10, 2021
Read about event More on this topic

Upcoming Event


Living standards and financial resilience across Europe

What has the impact of the pandemic on households’ financial resilience been, and how should policy makers respond?

Speakers: Zsolt Darvas, Maria Demertzis and Daniel Tomlinson Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels
Read article More on this topic More by this author


A Global Pandemic Alarm Bell

The appearance of new strains of the coronavirus in the United Kingdom, South Africa, and Brazil has given the world no choice but to design and implement a comprehensive global strategy. So, what's stopping that from happening?

By: Jean Pisani-Ferry Topic: Global Economics & Governance Date: January 26, 2021
Load more posts